The inhibition of angiotensin converting enzyme in chronic renal hypertension by a synthetic peptide.
Renal hypertension was produced in 14 Sprague-Dawley rats by ligating both poles of one kidney followed in one week by unilateral nephrectomy. Biweekly subcutaneous injections of SQ 20858 reduced the blood pressure in the chronic renal hypertensive animals. Upon discontinuing the injections the blood pressure rose to pretreatment levels. No angiotensin II activity was seen in seven of the renal group treated with SQ indicating a complete block in serum converting enzyme activity. Likewise, serum with only angiotensin I activity when added to normal serum containing converting enzyme, continued to show angiotensin I activity. It is concluded that SQ 20858 is effective in lowering blood pressure in chronic renal hypertensive rats presumably by partially inhibiting converting enzyme.
D000804:Angiotensin II / Q000097:blood; D000806:Angiotensin-Converting Enzyme Inhibitors; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002908:Chronic Disease; D006977:Hypertension, Renal / Q000188:drug therapy*; D007279:Injections, Subcutaneous; D008297:Male; D009392:Nephrectomy / Q000009:adverse effects; D010455:Peptides / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D012083:Renin / Q000494:pharmacology; D013997:Time Factors; D014688:Venoms / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D010455:Peptides; D014688:Venoms; D000804:Angiotensin II; D012083:Renin